Nearshoring Isn't a Strategy: What Pharma Manufacturers Need Before Moving Production to Mexico

Mexico is having a moment. With $784 million in pharmaceutical foreign direct investment in the first nine months of 2024 alone, and over $15 billion in cumulative pharma investment since 1999, the pitch is compelling: lower labor costs, geographic proximity to the US, a growing domestic market of 130 million people, and favorable trade agreements.

The 2026 USMCA Joint Review is adding fuel to the fire. Policy analysts are calling it a "pivotal opportunity" to strengthen regional pharmaceutical supply chains. The BIOSECURE Act is pushing companies away from Chinese manufacturing. Plan México is earmarking $400 million for medical device investment. COFEPRIS is modernizing its regulatory framework.

Every pharma executive in North America is asking the same question: should we move production to Mexico?

It's the wrong question.

The Nearshoring Mirage

Here's what the investment announcements and policy papers don't capture: moving production to a new geography is a capacity planning problem, not a real estate problem.

We've watched companies treat nearshoring as a location decision — find a site, build a facility, transfer processes, start producing. It sounds logical. It fails predictably.

A Brookings Institution analysis published in March 2026 noted that while Mexico is "strategically positioned" as a pharmaceutical manufacturing hub, it "has yet to fully develop advanced API capacity." That gap between positioning and capability is where billions of dollars go to die.

The typical nearshoring failure follows a pattern:

Month 1-6: Site selection, facility design, equipment procurement. Everything feels like progress.

Month 7-18: Process transfer begins. Product transfers to new manufacturing sites take up to two years — process transfer, scale-up, validation, regulatory filings. Each step reveals assumptions that don't hold in the new environment.

Month 19-30: The facility is operational but running at 35-45% utilization. Changeover times are longer than projected. Quality systems designed for the source facility don't translate cleanly. The economics that justified the investment start to erode.

Month 31+: Executive reviews. Finger-pointing. A consultant is hired to figure out what went wrong.

What went wrong is that nobody asked the right question at the start.

The Right Question

The question isn't "should we nearshore to Mexico?" It's: "What does our manufacturing network actually need, and does adding a Mexican facility solve that need?"

That distinction sounds subtle. It's not. It's the difference between a $200 million success story and a $200 million write-down.

When a pharmaceutical company maps its true manufacturing constraints — not assumed constraints, not constraints that existed three years ago, but the actual bottlenecks limiting output today — the answer is rarely "build a new facility somewhere cheaper."

More often, the real constraints are:

Scheduling complexity. A company producing 500+ formulations with 150+ new product launches annually doesn't need more square footage. It needs capacity intelligence — the ability to model how product mix changes ripple through changeover times, equipment utilization, and batch sequencing.

Network coordination overhead. Every facility you add doesn't just add capacity. It adds coordination costs: cross-border inventory buffers, regulatory compliance across multiple agencies, quality system synchronization, supply chain complexity. We've seen companies add 40% more manufacturing assets and lose 20% effective capacity because nobody modeled the network effects.

Utilization intelligence. Your existing facilities might be running at 85% utilization — but that number is meaningless without understanding where the bottleneck sits. A facility at 85% average utilization might have a single production route at 218% of practical capacity while three other routes sit below 50%. The solution isn't another facility. It's constraint elimination.

What Capacity Intelligence Looks Like

Before any nearshoring decision, manufacturers need answers to questions that spreadsheet analysis can't provide:

1. Where are your real bottlenecks?

Not where you think they are. Not where they were when you last analyzed capacity. Where they are right now, given your current product mix, projected demand, and regulatory commitments.

We've worked with manufacturers who discovered their "capacity problem" was actually a changeover problem — a scheduling constraint masquerading as a space constraint. The fix wasn't a $200 million facility in Mexico. It was lot size reformulation and route optimization in their existing plant.

2. What happens to your network when you add a node?

Adding a manufacturing facility in Mexico means your production decisions now span multiple regulatory environments, tax jurisdictions, supply chains, and quality systems. Have you modeled how a Mexican facility interacts with your existing network?

For manufacturers serving Latin America from multiple countries, the coordination cost of a new facility can exceed 15-20% of the expected capacity gain. That's before you account for the 18-24 months of process transfer and validation.

3. What's the minimum viable configuration?

If you do need a Mexican facility, what exactly should it produce? How many production routes? What lot sizes? What equipment specifications?

These aren't questions you answer with architect blueprints and equipment catalogs. They require simulation — modeling thousands of production scenarios to find the configuration that achieves your output targets without the utilization traps that plague most expansions.

When Mexico Is the Right Answer

None of this is an argument against manufacturing in Mexico. Mexico's advantages are real: USMCA trade benefits, proximity to the world's largest pharmaceutical market, competitive labor costs, and a regulatory environment that's actively modernizing.

The argument is against making the decision without capacity intelligence.

When we see nearshoring work, it follows a different pattern:

Phase 1: Constraint mapping. Before any site discussion, the manufacturer maps its true bottlenecks across its existing network. This usually reveals that 60-70% of the perceived capacity gap can be addressed through operational optimization — route restructuring, lot size reformulation, scheduling intelligence.

Phase 2: Network modeling. For the remaining capacity gap, the manufacturer models different network configurations. Where should the new node sit? What should it produce? How does it interact with existing facilities? What's the coordination cost?

Phase 3: Facility specification. Only after Phases 1 and 2 does the facility design begin — and it begins with specific answers: five dedicated production routes, not three. Lot sizes of 800, not 2,400. Equipment specified to actual projected utilization targets of 50-78%, not theoretical maximums.

The companies that follow this pattern don't just avoid the nearshoring trap. They build facilities that perform from day one because every design decision is backed by capacity simulation, not assumptions.

The USMCA Tailwind Is Real — But So Is the Risk

The July 2026 USMCA Joint Review will likely strengthen incentives for regional pharmaceutical manufacturing. A Section 232 national security review of the pharmaceutical sector could impose tariffs on APIs and finished drugs sourced from outside North America. The policy environment is moving decisively in Mexico's favor.

That's exactly why the risk of rushing is so high.

When incentives align this strongly, companies move fast. Fast is fine — as long as fast means "we already understand our manufacturing network and can make informed decisions quickly." Fast is dangerous when it means "we're building a facility because the policy window is open and our competitors are moving."

The companies that will win the next wave of LATAM pharmaceutical manufacturing aren't the ones that build the biggest facilities. They're the ones that build the right facilities — informed by capacity intelligence, designed for actual demand patterns, and integrated into manufacturing networks that actually work.

The question was never "should we nearshore to Mexico?"

The question is: do you understand your manufacturing capacity well enough to make that decision?